Earnings Releases·Nov 4, 2026, 7:05 AM ET

Seres Therapeutics — Third Quarter 2026 Earnings Summary

Reported a net loss of $16.3 million for Q3 2026 versus net income of $8.2 million in the prior year period; total revenue rose to $593,000 from $351,000, while R&D and G&A expenses decreased to $5.6 million and $5.4 million respectively due to cost reductions.
Cash and cash equivalents declined to $17.5 million as of September 30, 2026, from $45.8 million at year-end 2025, though operations are expected to be funded through Q1 2027 following a $12.5 million payment from Nestlé received in October.
Plans to submit next irEC study design to the FDA in Q1 2027, with SER-155 advancing into a prophylactic oral administration study for irEC and Phase 1b trial design pending funding for SER-428 and SER-603.
Early termination of the Cambridge, MA lease is expected to eliminate obligations by December 31, 2026, and reduce ongoing facility costs starting in 2027, alongside a $5.7 million non-cash impairment charge recorded for the lease exit.